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Cidofovir is frequently used to treat life-threatening human adenovirus (HAdV) infections in immunocom-
promised children after hematopoietic stem cell transplantation (HSCT). However, the antiviral effect irre-
spective of T cell reconstitution remains unresolved. Plasma HAdV DNA levels were monitored by real-time
quantitative PCR during 42 cidofovir treatment episodes for HAdV viremia in 36 pediatric allogeneic HSCT
recipients. HAdV load dynamics were related to T and natural killer (NK) cell reconstitution measured by ﬂow
cytometry. To evaluate the in vivo antiadenoviral effect of cidofovir, we focused on 20 cidofovir treatment
episodes lacking concurrent T cell reconstitution. During 2 to 10 weeks of follow-up in the absence of T cells,
HAdV load reduction (n ¼ 7) or stabilization (n ¼ 8) was observed in 15 of 20 treatments. Although HAdV load
reduction was always accompanied by NK cell expansion, HAdV load stabilization was measured in 2 children
lacking both T and NK cell reconstitution. In cases with T cell reconstitution, rapid HAdV load reduction
(n ¼ 14) or stabilization (n ¼ 6) was observed in 20 of 22 treatments. In the absence of T cells, cidofovir
treatment was associated with HAdV viremia control in the majority of cases. Although the contribution of NK
cells cannot be excluded, cidofovir has the potential to mediate HAdV load stabilization in the time pending
T cell reconstitution.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Human adenoviruses (HAdV) are nonenveloped double-
stranded DNA viruses. Currently, more than 50 serotypes
have been described. In healthy individuals, HAdV infections
cause self-limiting infections, such as conjunctivitis, upper
respiratory tract, urinary tract, or gastrointestinal infections
[1]. In pediatric hematopoietic stem cell transplantation
(HSCT) recipients, HAdV reactivations or primary infections
can progress to viremia and disseminated disease. It is
broadly accepted that T cells are essential for the protection
from and clearance of HAdV viremia [2-4]. However, in the
absence of T cell surveillance, the mortality of HAdV viremia
is high because of progression to HAdV-related multiorgan
failure [4-9].dgments on page 298.
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ty for Blood and Marrow Transplantation.The adoptive transfer of donor-derived adenovirus-spe-
ciﬁc T cells is a promising treatment [3-10], but it is not
available in all transplantation centers. Therefore, preemp-
tive pharmacological treatment is of great importance for the
majority of patients with HAdV viremia. To this end, ribavirin
and cidofovir have been explored. The evidence for a bene-
ﬁcial effect of ribavirin is limited to case reports and ribavirin
could not prevent the progression of HAdV viremia in the
absence of lymphocyte reconstitution [11]. Cidofovir (Vistide,
Gilead Sciences Inc, Foster City, CA), a monophosphate
nucleotide analogue with in vitro antiviral activity against
different HAdV strains [12-15], is a widely used antiviral
agent for HAdV infections after HSCT.
A number of studies have addressed the antiadenoviral
effect of cidofovir, but results are highly variable, with
treatment successes ranging from 24% to 98% [16-22]. The
discrepancies in cidofovir’s effectiveness might be related to
the fact that HAdV viremia and cidofovir treatment generally
occur during the critical phase of lymphocyte reconstitution
after HSCT [4-7]. When T cell reconstitution is not taken into
Table 1
Patient and Cidofovir Treatment Characteristics
Characteristics Value
Patient characteristics (n ¼ 36)
Age, median (range), yr 4.5 (.5-18)
HSCT indication
Primary immunodeﬁciency 8 (22%)
Benign hematological disorder 12 (33%)
Hematological malignancy 16 (44%)
Conditioning
Reduced intensity 6 (17%)
Myeloablative 30 (83%)
Donor type
Identical related donor 2 (6%)
Other related donor 7 (19%)
Matched unrelated donor 27 (75%)
Graft source
Bone marrow, T cellereplete 16 (44%)
Bone marrow, T celledepleted 1 (3%)
PBSC, T cellereplete 2 (6%)
PBSC, T celledepleted 8 (22%)
Cord blood 9 (25%)
Serotherapy
Antithymocyte globulin 23 (64%)
Alemtuzumab 13 (36%)
GVHD prophylaxis
None 4 (11%)
CsA 3 (8%)
CsA þ methotrexate 18 (50%)
CsA þ methylprednisolone 9 (25%)
CsA þ MMF 2 (6%)
Acute GVHD  grade II 5 (14%)
Cidofovir treatment
1 Episode 30 (83%)
2 Episodes 6 (17%)
First day plasma HAdV DNA level >1.7 log c/mL*,
median (range)
20 (3-96)
First day plasma HAdV DNA level 2x > 3 log
c/mL*, median (range)
28 (8-117)
First day of ﬁrst cidofovir treatment episode*,
median (range)
29 (7-121)
Final outcome
HAdV clearance 27 (75%)
Death from HAdV/MOF 6 (17%)
Death from other cause 3 (8%)
Cidofovir-treatment episodes (n ¼ 42)
Day start cidofovir*, median (range) 31 (7-214)
Plasma HAdV DNA level at start, median (range),
log c/mL
4.1 (1.7-6.5)
Treatment duration, median (range), d 16 (1-99)
PBSC indicates peripheral blood stem cells; GVHD, graft-versus-host
disease; CsA, cyclosporin A; MMF, mycophenolate mofetil; HAdV/MOF,
HAdV-related multiorgan failure.
Data presented are n (%) unless otherwise indicated.
* Day after HSCT.
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of cidofovir. An unbiased evaluation of the in vivo anti-
adenoviral effect of cidofovir is required because the use
of cidofovir is associated with considerable nephrotoxicity
[21-24].
In this study, we aimed to evaluate the in vivo antiviral
effect of cidofovir in patients with HAdV viremia after
pediatric HSCT without the confounding effect of concomi-
tant T cell reconstitution. Hereto, we monitored the change
of plasma HAdV DNA levels during cidofovir treatment,
focusing on cidofovir treatments in the absence of T cell
reconstitution.
METHODS
Ethics Statement
Transplantations were performed according to European Society for
Blood and Marrow Transplantation guidelines. Peripheral blood samples
were routinely obtained. Data were analyzed after approval by the institu-
tional review board (protocol P01.028 and P02.099). Informed consent was
provided by the patient and/or a parent or guardian.
Patients and Cidofovir Treatment
Between January 2003 and December 2012, 321 children received 363
transplantations at the pediatric HSCT unit of the Leiden University Medical
Center. Thirty-nine HSCT recipients were treated with cidofovir for HAdV
viremia. One patient was not evaluable, as she died from pre-existent
neurodegenerative disease within the ﬁrst 2 weeks of treatment. From 2
other patients, no follow-up of the plasma HAdV DNA levels (HAdV load)
was available, leaving 36 evaluable HSCT recipients. Six patients received 2
separate cidofovir treatment episodes for the same HAdV viremia and were
analyzed twice. In total, 42 cidofovir treatment episodes were analyzed
(Table 1).
In general, cidofovir treatment was initiated preemptively when the
HAdV load was 3 log (1000) viral DNA copies/mL (c/mL) at 2 consecutive
time points [6]. Reasons to stop treatment were the following: >1 log HAdV
load reduction accompanied by a dynamic increase in lymphocyte numbers,
HAdV load stabilization at levels below 3 log c/mL, nephrotoxicity, or
treatment failure. Cidofovir was administered intravenously thriceweekly at
1 mg/kg body weight [18]. Supportive care consisted of hyperhydrationwith
intravenous saline (3 L/m2 body surface per 24 hours) and oral probenecid
(25 mg/kg) at 3, þ1, and þ8 hours from the start of cidofovir infusion [23].
Other antiviral drugs were discontinued during cidofovir treatment. See
Supplemental Methods and Supplemental Table S1 for a detailed description
of patient inclusion and HSCT characteristics.
Monitoring of HAdV Plasma DNA Levels and Lymphocyte Reconstitution
HAdV reactivations were routinely monitored through twice weekly
plasma screening for viral DNA by real time quantitative PCR as described
previously [25]. The lower level of detection of this assay was 1.7 log viral
DNA c/mL. Monitoring was initiated at day þ3 after HSCT and continued
until T cells reached 300 cells/mL of peripheral blood. To monitor immune
reconstitution, peripheral blood white blood cell counts, including full
leukocyte differentiations, were performed 2 to 3 times per week. The lower
level of detection of lymphocytes was 10 to 20 cells/mL. Flow cytometric
analysis was performed weekly to quantify (natural killer) NK and T cell
reconstitution as described in the Supplemental Methods and Supplemental
Table S2. T cells were deﬁned as CD3þ cells in the CD45þ CD33/CD235a/
CD14- lymphocyte gate and NK cells were deﬁned as CD3- CD56þ cells in the
lymphocyte gate.
Deﬁnitions of HAdV Load Dynamics and Lymphocyte Reconstitution
during Cidofovir Treatment
HAdV load dynamics was evaluated during cidofovir treatment.
Reduction and increase were deﬁned as a  1 log (10-fold) change of the
HAdV load. Stabilization was deﬁned as a <1 log change in HAdV load. Both
reduction and stabilization of the HAdV load were regarded as viremia
control. To discriminate between the (potential) effect of T cell reconstitu-
tion and cidofovir treatment on HAdV load dynamics, we applied the low
threshold of 50 T cells/mL of peripheral blood to deﬁne T cell reconstitution.
We ﬁrst analyzed HAdV load dynamics in 42 cidofovir treatments
without (n ¼ 20) and with (n ¼ 22) T cell reconstitution in the ﬁrst 2 weeks
after treatment initiation. Subsequently, we focused on the 20 cidofovir
treatments in the absence of concomitant T cell reconstitution. In this group,
the HAdV load change was evaluated between treatment initiation and
1 week after the last dose of cidofovir. In cases with T cell reconstitutionbefore the end of treatment (n ¼ 6), follow-up was stopped 1 week before
T cell numbers reached 50 cells/mL to exclude the confounding effect of
T cells on the HAdV load.
Statistical Analysis
Statistical analysis was performed using SPSS Statistics 20 (IBM SPSS
Inc., Chicago, IL). GraphPad Prism 6.00 (GraphPad Software, San Diego, CA)
was used to construct ﬁgures. Because data did not follow Gaussian distri-
bution, the Mann-Whitney U test was used for the analysis of numerical
parameters. Pearson’s chi-square tests were used for analysis of categorical
parameters.
RESULTS
Characteristics of Cidofovir-treated Patients
The effect of cidofovir treatment on the HAdV load was
evaluated in 36 HSCT recipients, of whom the characteristics
are summarized in Table 1 and Supplemental Table S1. Six
patients received a second cidofovir treatment episode
Table 2
Details of human adenovirus viremia, cidofovir treatment, lymphocyte reconstitution and HAdV load dynamics
UPN HAdV Viremia CDV Treatment Lymphocyte Reconst. HAdV Load Change#
First Day
PCRþ*
Day PCR
2 >3 Log*
Load at
Start CDVy
Sero-
type
Species Treatment
No.
Day
Start*
Durationz T Cellx NK Cellk Steroids{ Day 14z Last Day
Follow-upz,**
Reason Stop
Follow-up**
T cells <50 cells/mL
14 days after start
cidofovir
543.1a 14 19 5.9 31 A 1 28 9 - þ - Y Y (14) Stop CDV
549.1 19 30 3.8 2 C 1 30 7 - þ - Y Y (14) Stop CDV
555.1 8 23 3.6 31 A 1 28 7 - þ - Y Y (14) Stop CDV
808.1 12 23 4.2 ? ? 1 23 21 - þ - Y Y (28) Stop CDV
600.1a 26 29 3.8 1 C 1 30 49 - þ þ ¼ Y (56) Stop CDV
616.1 13 20 4.4 3,31 B,C 1 17 27 - þ þ ¼ Y (28) T cell 50
721.1 39 - 2.4 ? ? 1 44 37 - þ þ ¼ Y (42) Stop CDV
514.3 20 27 4.4 2 C 1 31 14 - þ - ¼ ¼ (21) Stop CDV
543.1b n.a. n.a. 5.7 2,31 A,C 2 55 41 - - - ¼ ¼ (35) T cell 50
554.2 17 53 5.4 1 C 1 53 8 - - - ¼ ¼ (14) Stop CDV
560.1 27 48 4.9 5 C 1 48 42 - þ þ ¼ ¼ (35) T cell 50
625.2 43 - 2.3 1 C 1 59 9 - þ - ¼ ¼ (14) Stop CDV
648.2 70 75 4.3 31 A 1 78 50 - - - ¼ ¼ (14) T cell 50
681.1a 24 34 2.9 ? ? 1 40 7 - - - ¼ ¼ (14) Stop CDV
545.1b n.a. n.a. 2.6 5,31 A,C 2 39 64 - - þ ¼ [ (70) Stop CDV
551.1 19 33 2.7 31 A 1 21 47 - þ - [ ¼ (56) Stop CDV
613.1 40 46 4.1 5 C 1 44 17 - - þ [ [ (21) Stop CDV
719.1 5 8 4.0 31 A 1 7 28 - þ - [ [ (14) T cell 50
799.1 25 39 2.1 31 A 1 28 40 - - - [ [ (14) T cell 50
804.1 7 16 3.8 31 A 1 17 11 - þ - [ [ (21) Stop CDV
T cells 50 cells/mL
14 days after start
cidofovir
558.1 14 19 1.7 31 A 1 23 7 þ þ - c n.a. T cell 50
586.1 61 75 4.5 1 C 1 77 12 þ - - c n.a. T cell 50
648.1 6 - 2.8 31 A 1 17 14 þ þ þ c n.a. T cell 50
681.1b n.a. n.a. 2.3 ? ? 2 95 3 þ - - c n.a. T cell 50
697.1 5 23 4.3 ? ? 1 21 12 þ - - c n.a. T cell 50
732.1 10 20 4.4 ? ? 1 19 1 þ þ - c n.a. T cell 50
787.1b n.a. n.a. 2.4 ? ? 2 112 21 þ - - c n.a. T cell 50
816.1 5 22 4.2 31 A 1 23 11 þ þ - c n.a. T cell 50
817.1 34 37 3.3 ? ? 1 38 10 þ - - c n.a. T cell 50
515.2 12 16 6.5 1,2 C 1 16 24 þ þ þ Y n.a. T cell 50
587.1 20 - 4.1 31 A 1 31 7 þ þ - Y n.a. T cell 50
594.1b n.a. n.a. 6.0 1 C 2 214 73 þ - - Y n.a. T cell 50
600.1b n.a. n.a. 4.9 1 C 2 100 10 þ - - Y n.a. T cell 50
823.1 20 23 4.9 ? ? 1 22 12 þ þ - Y n.a. T cell 50
515.1 65 72 4.3 2 C 1 79 48 þ - þ ¼ n.a. T cell 50
545.1a 3 10 3.9 5 C 1 10 15 þ - - ¼ n.a. T cell 50
594.1a 21 28 3.9 1 C 1 32 80 þ þ þ ¼ n.a. T cell 50
597.1 5 12 4.2 31 A 1 8 99 þ - þ ¼ n.a. T cell 50
686.2 87 101 3.6 2 C 1 107 15 þ þ - ¼ n.a. T cell 50
787.1a 18 20 3.1 1 C 1 20 28 þ - þ ¼ n.a. T cell 50
634.1 96 117 5.4 2 C 1 121 36 þ - þ [ n.a. T cell 50
671.1 52 66 2.3 1 C 1 48 70 þ - þ [ n.a. T cell 50
UPN indicates unique patient number; n.a., not applicable; ?, not analyzed; CDV, cidofovir.
Treatments are ordered based on T cell reconstitution and HAdV load change. The decimal denotes the ﬁrst, second or third HSCT and the letter indicates the cidofovir treatment episode.
* Days after hematopoietic stem cell transplantation (HSCT).
y Plasma HAdV DNA levels in log copies per millilter.
z Days from start cidofovir treatment.
x T cell numbers in peripheral blood 50 cells/mL within 14 days after treatment initiation.
k 5-fold expansion of NK cell number in peripheral blood.
{ Prednisone 1 mg/kg body weight during cidofovir treatment.
# Reduction (Y)/Increase ([): plasma HAdV DNA levels changed1 log c/mL after initiation of cidofovir treatment. Stabilization (¼):<1 log c/mL change of HAdV load. Clearance (c): plasma HAdV DNA levels below lower limit
of detection at 2 consecutive time points.
** Follow-up was stopped at 1 week after the last dose of cidofovir or 1 week before T cell numbers reached 50 cells/mL.
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Figure 1. HAdV load dynamics in relation to T cell reconstitution. (A) Change
of plasma human adenovirus DNA levels (HAdV load) between the start of
treatment (day 0) and day 14 of cidofovir treatment in cases with T cell
numbers <50 cells/mL (n ¼ 20, left bar) and T cell numbers 50 cells/mL
(n ¼ 22, right bar) within this time period. HAdV load change: clearance:
dashed, 1 log reduction: white, stabilization: gray, 1 log increase: black.
P value: Pearson’s chi-square test. (B) Change of HAdV load between day 0 and
14 in 22 cidofovir treatments with T cell numbers 50 cells/mL. Solid lines:
cases without steroid treatment. Interrupted lines: methylprednisolone
>1 mg/kg of body weight. Shaded area: HAdV load below limit of detection
(1.7 log c/mL). (C) Change of T cell numbers between day 0 and 14 in 22
cidofovir treatments with T cell reconstitution. Solid lines: cases without
steroid treatment. Interrupted lines: methylprednisolone >1 mg/kg of body
weight. Shaded area: T cells below limit of detection (10 cells/mL).
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treatments. Cidofovir treatment was initiated at a median of
31 (range, 7 to 214) days after HSCT. At treatment initiation,
the HAdV loadwasmedian 4.1 (range,1.7 to 6.5) log c/mL and
median treatment duration was 16 (range, 1 to 99) days.
Forty of 42 cases received  1 week (3 doses) of cidofovir
(Tables 1, 2).
HAdV Load Dynamics in Relation to T Cell Reconstitution
T cells have been demonstrated to play a crucial role in
viral control and could form a major confounder in the
analysis of the antiviral effect of cidofovir. To test this hy-
pothesis, we ﬁrst divided the 42 cidofovir treatments in cases
without (n¼ 20) andwith (n¼ 22) Tcell reconstitution in the
ﬁrst 2 weeks after treatment initiation (Table 2). The groups
did not differ with respect to HSCT-related parameters and
HAdV viremia characteristics (Supplemental Table S3).
In 11 of 20 cidofovir treatments (55%) with T cell numbers
below 50 cells/mL, plasma HAdV DNA levels were stable in
the ﬁrst 2 weeks after treatment initiation. The HAdV load
increased  1 log c/mL in 5 of 20 treatments (25%) and HAdV
load reductiondbut no clearancedwas measured in 4 of 20
treatments (20%) without T cell reconstitution (Figure 1A).
In contrast, in 14 of 22 cidofovir treatments (64%) with
concomitant T cell reconstitution, HAdV load reduction or
HAdV clearance was observed within 2 weeks after treat-
ment initiation. The HAdV load was stable in 6 of 22 treat-
ments (27%) with T cell reconstitution and increased 1 log
in only 2 of 22 cases (9%), who both received high-dose
(>1 mg/kg methylprednisolone) steroid treatment
(Figure 1B,C). Hence, it can be concluded that the evaluation
of the antiviral effect of cidofovir treatment is strongly
inﬂuenced by T cell reconstitution (P ¼ .008, Figure 1A).
HAdV Load Dynamics in the Absence of T Cell
Reconstitution
To exclude the confounding effect of T cells, HAdV load
dynamics was further analyzed in the 20 cidofovir treat-
ments with < 50 T cells/mL of peripheral blood (Table 2,
Figure 2). In these cases, the evaluation period was extended
from 14 days used in the previous section to the time frame
between treatment initiation and 1 week after the last dose
of cidofovir (n¼ 14) or 1 week before T cell numbers reached
50 cells/mL (n ¼ 6).
A 1 log HAdV load reduction was observed in 7 of 20
treatments (35%) during a median 28-day evaluation period
in the absence of T cells (Figure 2A). In 8 of 20 cidofovir
treatments (40%), the HAdV load did not change signiﬁcantly
between the start and end of the evaluation period (median
18 days, Figure 2B). In the 5 remaining cases (25%), the HAdV
load increased 1 log despite cidofovir treatment during
median 21 days of follow-up in the absence of T cells
(Figure 2C).
NK Cell Expansion during HAdV Control in the Absence of
T Cell Reconstitution
In the majority of the cases without T cell reconstitution,
CD3CD56þ NK cells were already present at the start of
cidofovir treatment (Figure 2D-F). Reduction of the HAdV
load during cidofovir treatment coincided with a dynamic
increase in NK cell numbers in all 7 cases (8 to 29-fold NK cell
expansion, Figure 2D). In comparison, NK cell expansion was
observed in 4 of 8 cidofovir treatments with HAdV load
stabilization (Figure 2E) and 2 of 5 treatments with HAdV
load increase (Figure 2F, P ¼ .05).HAdV Load Stabilization in the Absence of Both T and NK
Cells
We ﬁnally analyzed the antiviral effect of cidofovir on the
HAdV load in HSCT recipients lacking both T and NK cell
reconstitution to exclude the possible contribution of NK
cells to HAdV control as well. Two HSCT recipients fulﬁlled
these criteria. In patient A (UPN 600.1a), no engraftment
Figure 2. HAdV control in the absence of T cells. (A-C) Plasma human HAdV DNA levels in 20 cidofovir treatments with T cell numbers <50 cells/mL. Follow-up was
stopped at 1 week after the last dose of cidofovir or 1 week before T cell numbers reached 50 cells/mL. HAdV load change: 1 log reduction (A, n ¼ 7), stabilization
(B, n ¼ 8) or 1 log increase (C, n ¼ 5). Solid lines: cases with 5 fold NK cell expansion, interrupted lines: cases without NK cell expansion. Vertical dotted line: start
of treatment. Shaded area: HAdV load below limit of detection (1.7 log c/mL). (D-F) Absolute numbers of NK cells in peripheral blood in cases with HAdV load
reduction (D), stabilization (E) and increase (F). Solid lines: cases with 5 fold NK cell expansion, interrupted lines: cases without NK cell expansion. Identical symbols
in corresponding ﬁgures represent individual cases. Vertical dotted line: start of treatment. Shaded area: NK cells below limit of detection (10 cells/mL).
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cidofovir treatment in the absence of any lymphocytes
(Figure 2A,D [open diamonds]; Supplemental Figure 1D). The
viremia was ultimately cleared after lymphocyte reconsti-
tution following a retransplantation. In patient B (UPN
545.1b), a graft rejection was treated with the lymphocyte
depleting antibody alemtuzumab. The HAdV load was stable
in the absence of lymphocytes over a 4-week period, after
which HAdV dissemination occurred under cidofovir
treatment (Figure 2C,F [open diamonds]; Supplemental
Figure 1B).
DISCUSSION
Here, we report a systematic analysis of the effect of
cidofovir treatment on HAdV viremia after HSCT, using
plasma viral DNA levels as an objective parameter while
taking concomitant lymphocyte reconstitution into account.
In line with our hypothesis, rapid HAdV load reduction and
HAdV clearance during cidofovir treatment were associated
with concurrent T cell reconstitution. In the absence of T cell
reconstitution, the HAdV viremia was controlled in 75% of
cidofovir treatments, which can be attributed to cidofovir
although a role of NK cell reconstitution cannot be excluded.
Of note, in 2 cases, HAdV load stabilization was observed
during a >3-week cidofovir treatment in the absence of both
NK and T cells.
Because of the strong correlation between T cell recon-
stitution and HAdV load reduction, as reported earlier [2-4]
and supported by our data, we focused our analysis on the20 cidofovir treatment episodes in HSCT recipients lacking T
cell reconstitution. In view of the often fatal outcome of a
progressing HAdV viremia [9], HAdV load reduction or sta-
bilization can be regarded as a beneﬁcial result. In line with
the in vitro virostatic capacity of cidofovir [12-15], control of
the HAdV viremia was observed in 15 of 20 cidofovir treat-
ments in the absence of T cell reconstitution. However,
reduction of the HAdV load (n¼ 7) always coincidedwith a
5-fold increase of NK cell numbers in the peripheral blood.
Consequently, the contribution of NK cell reconstitution to
HAdV control in HSCT recipients without Tcell reconstitution
cannot be excluded. Usually, NK cells are the ﬁrst lympho-
cytes to reach normal levels after HSCT [26,27]. Although the
NK cell response to HAdV is not as well described as the NK
cellemediated control of other viruses, such as inﬂuenza,
cytomegalovirus, and hepatitis C virus [28-30], a limited
number of studies reported NK cell activity against HAdV
infected cells [31-33]. Our data further support a role for NK
cells in the initial HAdV control in patients with a delayed T
cell reconstitution. At the same time, NK cell expansion did
not always coincide with HAdV load reduction, and the
presence of NK cells was no guarantee for HAdV load
stabilization.
In many studies, ﬁnal outcome of HAdV viremia is used as
a primary endpoint of cidofovir effectiveness, and concomi-
tant lymphocyte reconstitution is often ignored. This bears
the risk to overestimate the in vivo antiviral effect of cido-
fovir. Indeed, Walls et al. reported the clearance of HAdV
viremia in 8 of 9 pediatric HSCT recipients with HAdV loads
G. Lugthart et al. / Biol Blood Marrow Transplant 21 (2015) 293e299298>3 log c/mL in the absence of antiviral therapy [34]. For this
reason, an unbiased evaluation of the antiviral capacity of
cidofovirdand other pharmacological interventionsdfor
human adenoviral infections after HSCT is only possible by
monitoring HAdV load dynamics in patients who lack
concomitant lymphocyte reconstitution. Only 2 patients in
our cohort met this condition. In both cases, the HAdV
viremia remained stable over a 3 to 4-week period. Conse-
quently, cidofovir may also have contributed to the HAdV
load stabilization observed in HSCT recipients lacking T cell
reconstitution or with suppressed antiviral T cell responses
due to high-dose systemic steroids [35-37].
Of note, cidofovir treatment could not prevent the pro-
gression of HAdV viremia in 7 of 42 cidofovir treatments
(17%), all in the absence of T cell reconstitution or during
high-dose steroid treatment. With respect to the cause of
these treatment failures, no ﬁrm conclusions can be drawn.
In vitro studies reported comparable cidofovir susceptibility
between different HAdV species [12-15]. In our cohort,
cidofovir treatment failures were observed both in patients
with HAdV species A as well as thosewith species C.Whereas
cidofovir resistant HAdV strains have been generated in vitro
[38], no resistance was reported in clinical HAdV isolates
from cidofovir-treated HSCT recipients [12-15]. Possibly,
interpatient variations in cidofovir pharmacokinetics may
have contributed to failure of cidofovir treatment as well.
In view of the nephrotoxicity of cidofovir [21-24], the
observed treatment failures emphasize the need for new and
less toxic pharmacological interventions, such as brincido-
fovir (CMX001), the orally bioavailable lipid conjugate of
cidofovir [39], as well as adoptive immunotherapy-based
interventions [3,10] for patients with a delayed T cell
reconstitution.
The sensitive PCR methods used for the virological
monitoring after HSCT carry the risk of overtreatment, which
might lead to avoidable toxicity [34,40]. Longitudinal moni-
toring of lymphocyte reconstitution can identify patients
with better odds on a favorable outcome of HAdV viremia.
Indeed, the presence of even a low number of T cells (50
cells/mL) in patients without steroid treatment was associ-
ated with a rapid HAdV load reduction. The frequent moni-
toring of T cell reconstitution can be a valuable tool to
prevent the unnecessary installment or continuation of
cidofovir treatment. A comparable approach has already
been applied successfully in the management of cytomega-
lovirus and Epstein-Barr virus infections after HSCT [41,42].
Altogether, a subgroup of patients with HAdV viremia
after HSCT might beneﬁt from cidofovir treatment through a
stabilization of the HAdV load pending lymphocyte recon-
stitution. Nevertheless, T cell reconstitution remains essen-
tial for viral clearance. For clinical decision-making, the
combined monitoring of plasma HAdV DNA levels and
lymphocyte reconstitution provides an objective tool for the
guidance of personalized antiviral treatment and prevention
of unnecessary exposure to cidofovir.
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